Navigation Links
Influenza Infection Costs Employers Billions Each Year; Working Adults Largest Group Not Immunized Annually
Date:2/25/2009

AMERICAN LUNG ASSOCIATION OF MICHIGAN URGES DETROIT EMPLOYERS TO SEE INFLUENZA AS A CREDIBLE BUSINESS THREAT

DETROIT, Feb. 24 /PRNewswire/ -- Influenza results in billions of dollars in lost wages every year, and recent studies found that an estimated 75 million missed workdays a year, and about 200 million days of restricted activity, are due to this vaccine-preventable disease. Yet vaccination rates remain alarmingly low, especially among working adults. In fact, adults between the ages of 18 and 49, typical ages of those in the workplace, have the lowest influenza immunization rates of any other age group.(1,2)

To help prevent influenza from spreading throughout the workplace and elsewhere, various local employers, including Wayne State University, have partnered with the American Lung Association of Michigan to bring Faces of Influenza to the Detroit area. Annual influenza vaccination is the best protection available against the disease, and provides a proven business advantage both to companies and their employees.

With stories of economic hardships widespread in Detroit, the American Lung Association of Michigan's Faces of Influenza program urges those who have not been vaccinated yet to schedule an appointment. Locally, between 47,563 and 190,254 Detroit area residents will suffer from influenza in an average year - resulting in missed days at work and lost wages.

"It is critical that our staff be vaccinated against the flu because it is easily spread among employees, and then home to more vulnerable members of their families," said Laura Bertalan, of the American Lung Association of Michigan. "By making sure we are vaccinated, we have a significant impact on lessening the severity and length of the flu in our community."

Influenza is not the common cold. It's serious. Each year, approximately 226,000 people in the U.S. are hospitalized with complications f
'/>"/>

SOURCE American Lung Association of Michigan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Influenza Infection Costs Employees Billions Each Year; Working Adults Largest Group Not Immunized Annually
2. Recently Reported Childhood Deaths from Influenza Are a Stark Reminder to Vaccinate Now
3. eFoodSafety Enters Research Agreement with University of Minnesota to Test New Food-Grade Antiviral for Swine Influenza Virus
4. Study shows workplace benefits of influenza vaccination in 50-64 year olds
5. Study Finds More Effective Treatment for Pneumonia Following Influenza
6. Study finds more effective treatment for pneumonia following influenza
7. Health Department Reports South-Central Regions First Lab-Confirmed Influenza Case of the Season
8. NACCHO to Support Influenza Vaccination Efforts With Donation of Up to One Million Doses of FluMist(R)
9. Video: Childhood Influenza Immunization Coalition Supports Second Annual Childrens Flu Vaccination Day
10. The American Lung Association of the Central States Encourages Kansas City Residents to See Themselves Among the Many Faces of Influenza
11. Houston Mother Who Nearly Lost Her Daughter to Influenza Joins American Lung Associations Faces of Influenza Campaign to Promote Annual Vaccination

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...cco has been the life-long focus of his research a...Lombardi Comprehensive Cancer Center at Georgetown...edit a special-edition of Cancer Epidemiology, Bi...research practices in tobacco science from researc...BP , a journal of the American Association for Can...
(Date:12/2/2009)... Reportlinker.com announces that a ...alogue: ,, Renal Disease Treatments: Products ...p0166824/Renal-Disease-Treatments-Products-and-The...n products and services, providing data for 2008 a...ket and compound annual growth rates (CAGRs) from ...
(Date:12/2/2009)... Reportlinker.com announces that a ...alogue: ,, Antibiotic Resistance and Antibioti...reportlinker.com/p0166825/Antibiotic-Resistance-an..., Provide an in-depth review of the global market...logies ,, Offer an analysis of antibiotics resi...
(Date:12/2/2009)...d cases, study finds , , WEDNESDAY, Dec....rvival rates for advanced lung cancer patients in ...udy has found. , Researchers analyzed data on m...on-small cell lung cancer (NSCLC) between 1990 and...ional Cancer Institute,s Surveillance, Epidemiolog...
(Date:12/2/2009)...etabolic syndrome, study finds , , WEDNE...n,t enough to keep overweight college football pla...tion that can lead to heart disease, a new study s...ion I colleges and found that two-thirds were obes...group of conditions that raise the risk for heart ...
Breaking Medicine News(10 mins):Health News:Lombardi's Shields leads special journal focused on tobacco research 2Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 2Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 3Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 4Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 5Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 6Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 7Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 8Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 9Health News:Reportlinker Adds Renal Disease Treatments: Products and Therapies 10Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 2Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 3Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 4Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 5Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 6Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 7Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 8Health News:Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies: Global Markets 9Health News:Gains Made in Lung Cancer Survival 2Health News:Oversized College Football Players May Face Heart Risks 2
...revent liver failure in thousands of people with H...dy published tomorrow (1 August) in the Journal o...at warfarin reduces the scarring on the liver caus...llowing the new findings in mouse models, the Impe...
... saves over $2 million in conducting the company,s...IV and safety registry - with Clinipace,s TEMPO re...h Triangle Park, NC (PRWEB) July 31, 2008 -- Clini...rect costs associated with conducing two research ...
...are Health,Systems, Inc. (Amex: ADK ), an Ohio ba...ny, today announced the refinancing of one of its ...ld, LLC, is a 50-bed single story nursing home,fac...tchen, laundry, activity and therapy rooms, a new ...
...an Association,of PPOs (AAPPO) today announced the...utives on strategies to improve the value of clini...g Value Initiative will inform AAPPO,members and p..., AAPPO President and CEO Karen Greenrose, commen...
...rtner decreases the risk of developing Alzheimer,s...study by Krister Hkansson, researcher in psycholog...den. The results were presented for the first time... in this field, and the results are astounding. Th...
...l and media,outreach efforts by The Soap and Deter...m ) on the health benefits of hand hygiene have be...a Award of Excellence., The honor is given annual... training, business and social,innovation, knowled...
Other Medicine News:Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 3Health News:On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace 2Health News:On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace 3Health News:On-X Life Technologies Significantly Reduces Study Management Costs with TEMPO from Clinipace 4Health News:AdCare Health Systems, Inc. Announces the Refinancing of a Nursing Home in Ohio 2Health News:AAPPO Launches Short Course Conference Call Series on Value-added Strategies for PPOs 2Health News:Living with a partner reduces risk of Alzheimer's 2Health News:SDA Hygiene Outreach Efforts Honored with Award of Excellence 2Health News:SDA Hygiene Outreach Efforts Honored with Award of Excellence 3
(Date:12/2/2009)... , PALO ALTO, Calif., Dec. 2 /PRNewswire-First...hat on November 25, 2009, Varian, Inc. filed with ...nual Report on Form 10-K for the fiscal year ended...sed through the Company,s web site at www.varianin...," and then on "10-K" in the table shown. Stockho...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Report...port is available in its catalogue: ,, Hemoglo...http://www.reportlinker.com/p0164230/Hemoglobin-A1...e seriousness of affliction and the need for effec...rgence of a significant market for monitoring the ...
(Date:12/2/2009)... , NEW YORK, Dec. 2 Report...port is available in its catalogue: ,, Global.../www.reportlinker.com/p0166826/Global-Markets-for-...epth analysis of the global market for medications...ry disease ,, Contains global market forecasts ...
Breaking Medicine Technology:Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 2Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 3Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 4Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 5Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 6Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 7Reportlinker Adds Global Markets for Asthma and COPD Drugs 2Reportlinker Adds Global Markets for Asthma and COPD Drugs 3Reportlinker Adds Global Markets for Asthma and COPD Drugs 4Reportlinker Adds Global Markets for Asthma and COPD Drugs 5Reportlinker Adds Global Markets for Asthma and COPD Drugs 6Reportlinker Adds Global Markets for Asthma and COPD Drugs 7Reportlinker Adds Global Markets for Asthma and COPD Drugs 8Reportlinker Adds Global Markets for Asthma and COPD Drugs 9Reportlinker Adds Global Markets for Asthma and COPD Drugs 10Reportlinker Adds Global Markets for Asthma and COPD Drugs 11UC Davis researchers visualize formation of a new synapse 8885 1UC Davis researchers visualize formation of a new synapse 8885 2Group Health Cooperative Shows Investing in More Primary Care Pays for Itself 49287 1Group Health Cooperative Shows Investing in More Primary Care Pays for Itself 49287 2Group Health Cooperative Shows Investing in More Primary Care Pays for Itself 49287 3The power of prayer 3F 49285 1The power of prayer 3F 49285 2
..., Inc. today,announced that it has initiated a Pha...enance therapy in reducing the incidence of pulmon...tive pulmonary disease,(COPD). MP-376 is the compa...solution., The Phase 2, U.S. multi-center randomi...02) is expected to enroll approximately 300,COPD p...
...resented at AASLD annual meeting, Pivotal Phase I... those,who failed prior treatment, SAN FRANCISCO,... today reported that a planned interim analysis of...stigational oral hepatitis C,protease inhibitor, i...kedly increased sustained virologic response (SVR)...
Other Medicine Technology:Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD 2Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10
SmartLite Derm
Triactive
... latest evolution of Smartepil family by DEKA, a h...tion and transdermic vascular treatments. Thanks t...rtepil II Plus allows for carrying out non-invasiv...nts social life. The system is fitted with a wide ...
KOWA Automated Tonometer KT-500
Medicine Products: